Download MendeleyHighly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Wenglowsky, S., Ren, L., Grina, J., Hansen, J.D., Laird, E.R., Moreno, D., Dinkel, V., Gloor, S.L., Hastings, G., Rana, S., Rasor, K., Sturgis, H.L., Voegtli, W.C., Vigers, G., Willis, B., Mathieu, S., Rudolph, J.(2014) Bioorg Med Chem Lett 24: 1923-1927
- PubMed: 24675381
- DOI: https://doi.org/10.1016/j.bmcl.2014.03.007
- Primary Citation of Related Structures:
4PP7 - PubMed Abstract:
Herein we describe the design of a novel series of ATP competitive B-Raf inhibitors via structure-based methods. These 3-N-methylquinazoline-4(3H)-one based inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. Optimization led to the identification of compound 16, a potent, selective and orally available agent with excellent pharmacokinetic properties and robust tumor growth inhibition in xenograft studies. Our work also demonstrates that by replacing an aryl amide with an aryl sulfonamide, a multikinase inhibitor such as AZ-628, can be converted to a selective B-Raf inhibitor, a finding that should have broad application in kinase drug discovery.
Organizational Affiliation:
Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, United States.
